BC Innovations | Aug 23, 2017
Distillery Therapeutics


INDICATION: Poisoning In vitro and mouse studies suggest the antioxidant N -acetylcysteine could help prevent radiation-induced intestinal injury. In a mouse model of the indication, pretreatment with the reactive oxygen species (ROS) scavenger N -acetylcysteine...
BC Innovations | Apr 25, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell culture studies suggest cysteine, N -acetylcysteine and other thiol analogs could help treat tuberculosis (TB) and reduce resistance to the generic TB drugs rifampicin and isoniazid. In rifampicin-resistant Mycobacterium tuberculosis culture, isoniazid...
BC Innovations | Mar 5, 2015
Distillery Therapeutics

Therapeutics: Mucin

Pulmonary disease INDICATION: Cystic fibrosis (CF) Studies in patient samples and mice suggest methyl 6-thio-6-deoxy-α-D-galactopyranoside (TDG) could decrease mucus accumulation in CF patients. In patient sputum samples, TDG exhibited more potent and faster-acting mucolytic activity...
BC Week In Review | Jan 5, 2015
Clinical News

NHPN-1010: Phase I started

In November, Otologic said it began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single doses of 500, 1,000 and 1,500 mg oral HPN-07 alone and HPN-07 at the maximum tolerated dose (MTD) plus...
BC Week In Review | Nov 10, 2014
Company News

Doliage, Nicox deal

Nicox acquired French ophthalmic play Doliage for EUR5 million ($6.2 million) in newly issued Nicox shares. Nicox said the acquisition is part of its strategy to develop an ophthalmic commercial infrastructure in the five major...
BioCentury | Sep 8, 2014

Parsing Roche's IPF bet

InterMune Inc. 's third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche . The question now...
BC Innovations | Sep 4, 2014
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Circulating microRNA signature to diagnose acetaminophen poisoning An 11-miRNA signature could be used to identify acetaminophen poisoning earlier and with better sensitivity than measuring alanine aminotransferase...
BC Week In Review | Jan 27, 2014
Clinical News

Zoenasa Rectal Suspension: Completed Phase II enrollment

Altheus completed enrollment of about 120 patients in the double-blind, U.S. Phase II ZA201 trial comparing Zoenasa Rectal Gel vs. mesalamine enema for 6 weeks. Data are expected in March or early April. The product...
BioCentury | Nov 11, 2013

OrbiMed's high five

At a time when many life science VCs are raising smaller funds, OrbiMed Advisors closed what might be the largest pure venture fund in over a decade, raising more than $735 million from LPs who...
BioCentury | Aug 12, 2013

Signed and sealed

ProFibrix B.V. reached the one-yard line with its Fibrocaps based on €40 million in equity funding, but rather than amass commercial scale to compete in the surgical products market, the company accepted a takeout bid...
Items per page:
1 - 10 of 67